T. Rowe Price Associates’s Sage Therapeutics SAGE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | – | Sell |
|
|||||
|
2025
Q2 | $400K | Buy |
|
|||||
|
2025
Q1 | $312K | Sell |
|
|||||
|
2024
Q4 | $2.25M | Sell |
|
|||||
|
2024
Q3 | $3.25M | Sell |
|
|||||
|
2024
Q2 | $5.57M | Sell |
|
|||||
|
2024
Q1 | $15.2M | Buy |
|
|||||
|
2023
Q4 | $10.4M | Sell |
|
|||||
|
2023
Q3 | $12M | Sell |
|
|||||
|
2023
Q2 | $50.8M | Sell |
|
|||||
|
2023
Q1 | $80.1M | Buy |
|
|||||
|
2022
Q4 | $72.4M | Sell |
|
|||||
|
2022
Q3 | $83.8M | Buy |
|
|||||
|
2022
Q2 | $67.1M | Sell |
|
|||||
|
2022
Q1 | $71.4M | Buy |
|
|||||
|
2021
Q4 | $60.3M | Buy |
|
|||||
|
2021
Q3 | $62.3M | Sell |
|
|||||
|
2021
Q2 | $89.3M | Sell |
|
|||||
|
2021
Q1 | $180M | Buy |
|
|||||
|
2020
Q4 | $204M | Sell |
|
|||||
|
2020
Q3 | $156M | Sell |
|
|||||
|
2020
Q2 | $117M | Sell |
|
|||||
|
2020
Q1 | $85.1M | Sell |
|
|||||
|
2019
Q4 | $408M | Sell |
|
|||||
|
2019
Q3 | $1.05B | Sell |
|
|||||
|
2019
Q2 | $1.45B | Sell |
|
|||||
|
2019
Q1 | $1.32B | Buy |
|
|||||
|
2018
Q4 | $768M | Buy |
|
|||||
|
2018
Q3 | $1.1B | Buy |
|
|||||
|
2018
Q2 | $1.19B | Buy |
|
|||||
|
2018
Q1 | $1.15B | Buy |
|
|||||
|
2017
Q4 | $1.04B | Buy |
|
|||||
|
2017
Q3 | $291M | Buy |
|
|||||
|
2017
Q2 | $282M | Buy |
|
|||||
|
2017
Q1 | $237M | Buy |
|
|||||
|
2016
Q4 | $131M | Buy |
|
|||||
|
2016
Q3 | $64.5M | Buy |
|
|||||
|
2016
Q2 | $14.2M | Buy |
|
|||||
|
2016
Q1 | $12.2M | Hold |
|
|||||
|
2015
Q4 | $22.2M | Sell |
|
|||||
|
2015
Q3 | $31M | Buy |
|
|||||
|
2015
Q2 | $30.5M | Buy |
|
|||||
|
2015
Q1 | $4.51M | Buy |
|